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The orexin/hypocretin neuropeptides are produced by a cluster of neurons within the
lateral posterior hypothalamus and participate in neuronal regulation by activating their
receptors (OX1 and OX2 receptors). The orexin system projects widely through the brain
and functions as an interface between multiple regulatory systems including wakefulness,
energy balance, stress, reward, and emotion. Recent studies have demonstrated that
orexins and glutamate interact at the synaptic level and that orexins facilitate glutamate
actions. We tested the hypothesis that orexins modulate glutamate signaling via OX1
receptors by monitoring levels of glutamate in frontal cortex of freely moving mice
using enzyme coated biosensors under inhibited OX1 receptor conditions. MK-801, an
NMDA receptor antagonist, was administered subcutaneously (0.178mg/kg) to indirectly
disinhibit pyramidal neurons and therefore increase cortical glutamate release. In wild-type
mice, pretreatment with the OX1 receptor antagonist GSK-1059865 (10mg/kg S.C.) which
had no effect by itself, significantly attenuated the cortical glutamate release elicited by
MK-801. OX1 receptor knockout mice had a blunted glutamate release response to MK-801
and exhibited about half of the glutamate release observed in wild-type mice in agreement
with the data obtained with transient blockade of OX1 receptors. These results indicate
that pharmacological (transient) or genetic (permanent) inhibition of the OX1 receptor
similarly interfere with glutamatergic function in the cortex. Selectively targeting the
OX1 receptor with an antagonist may normalize hyperglutamatergic states and thus may
represent a novel therapeutic strategy for the treatment of various psychiatric disorders
associated with hyperactive states.
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INTRODUCTION
Orexins, also known as hypocretins, are two peptides (orexin
A and B) derived from a single precursor produced exclusively
in the hypothalamus (de Lecea et al., 1998). Orexins partici-
pate in neuronal regulation by activating their receptors (OX1
and OX2 receptors). The orexin system is emerging as a pow-
erful integrator of multiple physiological functions including
sleep/wakefulness states, energy balance, stress, reward, and emo-
tion (for latest review see Li et al., 2014). Orexin neurons project
broadly throughout the whole brain and can be modulated by
multiple humoral signals and neuronal inputs. Several key areas
from the limbic system (including the bed of the stria termi-
nalis, the amygdala, and the medial septum) send axons to orexin
cells (Sakurai et al., 2005). The majority of synapses on orexin
somata and dendrites are asymmetric with small, round, clear
vesicles that reflect excitatory neural transmission (Zhang et al.,
2005). Orexins and glutamate interact at the synaptic level where
orexins facilitate glutamatergic actions. In turn, glutamatergic
neurons regulate orexinergic neuronal activity via presynaptic
facilitation of glutamate release (Li et al., 2002). Early in vitro
experimental data have shown that orexin A increased glutamate
release from hypothalamic slices (van den Pol et al., 1998). In
rats, intravenous administration of orexin A increased glutamate
release in the amygdala, a brain region known to express OX
receptors, but not in the cerebellum where OX receptors are not
expressed (John et al., 2003). Intravenous injection of orexin A
also increased glutamate release in the locus coeruleus (Kodama
and Kimura, 2002) and it has been suggested that orexin neurons
and NMDA receptors interact together in the control of the locus
coeruleus noradrenergic activity (Tose et al., 2009). These actions
might be mediated via the OX1 receptors since this OX receptor
subtype is exclusively expressed in the locus coeruleus (Trivedi
et al., 1998). In the present study, we tested the hypothesis that
orexin modulates glutamate signaling in cortex via OX1 recep-
tors by monitoring levels of glutamate in the prefrontal cortex of
freely moving mice. In contrast to the locus coeruleus, in cortex
both OX receptor subtypes are expressed (Marcus et al., 2001)
and therefore the OX1 receptor might not be the only receptor
involved. We used an enzyme coated biosensors to monitor real
time change in glutamate release (Uslaner et al., 2012). MK-801,
an NMDA receptor antagonist, was administered to indirectly
disinhibit pyramidal neurons and increase glutamate release in
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cortex. In the first experiment we investigated the effect of tran-
sient inhibition of the OX1 receptor by systemic administration
of the selective and brain penetrant OX1 receptor antagonist
GSK-1059865 (Gozzi et al., 2011) on MK-801 induced glutamate
release in the cortex of wild-type mice. In a second experiment,
we investigated the effect of permanent inhibition of OX1 recep-
tors by comparing the effect of MK-801 on glutamate release in
the cortex of wild-type vs. OX1 receptor knockout mice.
METHODS
All animal experimental procedures were performed in accor-
dance with the Guide for the Care and Use of Laboratory Animals
adopted by the US National Institutes of Health.
Male wild-type mice and fully backcrossed OX1 receptor
knockout mice of the same age (8–12 weeks old) and strain
(Jackson Labs C57/Bl6) were singly housed at the time of exper-
imentation. Biosensor technology was used to measure real-
time change of glutamate release in the cortex of freely moving
mice as previously described (Uslaner et al., 2012). Each mouse
was given a subcutaneous injection of Buprenex (0.1mg/kg,
buprenorphine hydrochloride; Reckitt Benckiser Pharmaceuticals
Inc., Richmond, VA) 5min prior to anesthesia. Animals were
anesthetized with an isoflurane/air mixture and stereotaxically
implanted with a guide cannula (BAS) in the prefrontal cor-
tex (+1.54mm anterior, 0.5mm lateral, right hemisphere and
1.4mm ventral to Bregma, Supplemental Data Figure S1). A
grounding screw attached to the “headmount connector” was
inserted slightly anterior to the interaural line. The guide can-
nula and headmount connector were secured in place with dental
cement. Animals were allowed at least 5 days to recover from
surgery prior to experimentation.
The glutamate sensor (model #7004 Pinnacle Technology
Inc., Lawrence, KS) specification and hardware setup has been
described in detail previously (Naylor et al., 2011). Briefly, glu-
tamate biosensors act through enzyme mediated processing.
Glutamate is converted to hydrogen peroxide and detected by
oxidation at the Pt-Ir electrode. A selectively passive membrane
allows for exclusion of electroactive interferents. Prior to sen-
sor insertion, each biosensor was calibrated in vitro to verify
glutamate sensitivity and interference rejection. The biosen-
sors extended beyond the guide cannulas by 1mm. The after-
noon prior to experimentation, under light isoflurane anesthesia,
biosensors were inserted into the guide cannula of each animal
which was then returned to its home cage for sensor equilibra-
tion. Data acquisition started immediately and the animals were
maintained connected to the acquisition hardware overnight. The
sensor signal was processed by the 8401 Data Acquisition System
and data acquisition, storage, and analysis were performed by the
Pinnacle Acquisition Laboratory software suite. Experimentation
was conducted the following day between 8:00 am and 3:00 pm
(light cycle) in a controlled environment.
A group of wild-type mice was administered with saline (S.C.)
and monitored for a 90- min baseline period. Each animal was
then pretreated with the selective OX1 receptor antagonist (GSK-
1059865, 10mg/kg S.C.) or vehicle 30min prior to the injection
of MK-801 (0.178mg/kg, S.C.). The effect of GSK-1059865 on its
own (in the absence of MK-801) was also assessed in an across
study subject design. At the end of each test session, naïve ani-
mals toMK-801 receivedMK-801 (0.178mg/kg S.C.) as a positive
control test.
GSK-1059865 was synthetized at Janssen Research and
Development LLC and was formulated in 30% sulfobutylether
(7)-β-cyclodextrin (SBE) or 5% Pharmasolve, 20% Cremaphor
and 75% D5W. MK-801 was purchased from Sigma and formu-
lated in saline. All injection volumes were 10ml/kg. The doses
of GSK-1059865 (10mg/kg) and MK-801 (0.178mg/kg) were
selected based on literature data where biological activity has been
reported (Bonaventure et al., 2011; Gozzi et al., 2011; Uslaner
et al., 2012).
The study was done in the set of three experiments. For each
animal the area under the curve of the baseline change in glu-
tamate release over 1 h post MK-801 stimulation was calculated.
To assess whether the mean area under the curve differs for the
two treatment groups (GSK-1059865 and vehicle treatedmice) we
used One-Way ANOVA, blocking for the experiment effect. Two-
sided paired t-test was used to assess the effect of GSK-1059865
(vs. vehicle) on the area under the curve of glutamate release over
1 h time period.
A second experiment using OX1 receptor knockout and wild-
type mice was conducted as a within subject study design. All
animals received a subcutaneous saline injection, and were treated
with MK-801 (0.178mg/kg S.C.) 90min later. The area under the
curve was calculated for each animal and the two-sample one-
sided t-test was performed to compare the area under the curve
of changes in glutamate from baseline over 1 h between MK-801
stimulated OX1 receptor knockout and wild-type mice.
Changes in glutamate concentration were recorded as cur-
rent (nA) every second for at least 60min following the last
drug administration. The data were averaged into 2-min bins and
glutamate concentrations were calculated using post calibration
values.
At the completion of the experiment, each sensor was removed
from the guide cannula and calibrated in vitro for glutamate
sensitivity and interference rejection of ascorbate at 37◦C in a
circulating water bath. At the end of the experimentation, the
brains were coronally sectioned and sensor location was visually
verified. Sensor placements which were outside the targeted area
by ±0.2mm were not included.
RESULTS
We first investigated the effect of transient inhibition of the OX1
receptor with a selective brain penetrant OX1 receptor antagonist
on MK-801 induced glutamate release in the cortex of wild-type
animal (Figure 1A). In wild-type mice, GSK-1059865 (10mg/kg,
S.C.) significantly attenuated cortical glutamate release elicited
by MK-801 (0.178mg/kg S.C.) (Figure 1A, treatment group: F =
5.537, df = 1, p = 0.037; block: F = 3.677, df = 2, p = 0.057).
As compared to vehicle GSK-1059865 did not affect glutamate
release per se (Figure 1B, t = 1.784, df = 7, p = 0.118).
We then investigated the effect of permanent inhibition of the
OX1 receptor by comparing the effect of systemic administra-
tion of MK-801 (0.178mg/kg S.C.) on glutamate release in the
cortex of wild-type and OX1 receptor knockout mice (Figure 2).
Compared to wild-type mice, OX1 receptor knockout mice had
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FIGURE 1 | (A) Effect of GSK-1059865 (10mg/kg S.C.) on MK-801
(0.178mg/kg, S.C.) induced glutamate release in the cortex of freely
moving wild-type mice (within subject study design). GSK-1059865 was
administered at t = 0 and MK-801 was administered at t = 30min.
(B) Effect of GSK-1059865 (10mg/kg S.C.) on glutamate release in the
cortex of freely moving wild-type mice (across subject study design).
GSK-1059865 was administered at t = 0. Real-time measurements of
glutamate were conducted before and after compound administration.
Results are expressed as change in glutamate concentrations as
mean ± s.e.m. GSK-1059865 did not affect glutamate levels per se
(p = 0.118) but attenuated MK-801-induced increase in glutamate release
(p = 0.037).
a blunted glutamate release response to MK-801 (t = 1.981,
df = 9, p = 0.04). MK-801 still induced an increase in glutamate
release in OX1 receptor knockout mice but the magnitude of this
increase was in a range of about 30–50% of the release observed
in wild-type animals after 20min post treatment.
FIGURE 2 | Effect of MK-801 (0.178mg/kg, S.C.) on glutamate release
in the cortex of freely moving OX1 receptor knockout mice and
wild-type mice (within subject study design). Real-time measurements
of glutamate were conducted before and after compound administration
(MK-801 was administered at t = 0). Results are expressed as change in
glutamate concentrations as mean ± s.e.m. MK-801 response in OX1
receptor knockout mice was attenuated compared to wild-type mice
(p = 0.042).
DISCUSSION
In this study we used a pharmacological and genetic approach
to investigate the functional interaction between the OX1 and
NMDA receptors using MK-801 induced glutamate release in
mouse frontal cortex. In wild-type mice, transient inhibition of
the OX1 receptor with a selective OX1 receptor antagonist sig-
nificantly attenuated excessive cortical glutamate release elicited
by MK-801. Systemic administration of the selective OX1 recep-
tor antagonist had no effect on glutamate release on its own.
Permanent inhibition of OX1 receptor in OX1 receptor knock-
out mice resulted in a diminished glutamate release evoked by
MK-801 comparable to the response obtained with the OX1
receptor antagonist. Therefore, these data ruled out the possibil-
ity of a direct pharmacokinetic interaction between MK-801 and
GSK-1059865 in wild-type mice.
Brain penetration and biological activity of GSK-1059865 has
been recently demonstrated (Gozzi et al., 2011) and later con-
firmed in our lab in a similar dose range (Dugovic et al., 2014).
The biosensor technology used to monitor glutamate release
in this study is well established. Noteworthy, the effects of vehi-
cle on glutamate release are substantially greater in the first
experiment (Figure 1A) when compared to the second exper-
iment (Figure 1B). Inter-animal variability is common during
animal handling and injections as glutamate release has been
linked to an animal’s arousal state and individual stress response
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(Westerink and Cremers, 2007). Previous studies have shown that
MK-801 increased glutamate release in the rat cortex (Lopez-Gil
et al., 2007; Bonaventure et al., 2011) and nucleus accumbens
(Uslaner et al., 2012). The increase in cortical glutamatergic trans-
mission elicited through blockade of an excitatory glutamate
receptor (NMDA) results from an indirect effect of the NMDA
receptor antagonist on GABAergic interneurons (Krystal et al.,
2003). NMDA receptor antagonists attenuate the tonic activation
of inhibitory neurons (GABA) most likely in the hippocampus
and/or thalamus resulting in a disinhibition of glutamatergic
input in the medial prefrontal cortex. Noteworthy, MK-801 also
acts as a nicotinic acetylcholine receptor antagonist in addition to
its NMDA receptor antagonistic properties (Amador and Dani,
1991). Ketamine, another NMDA receptor antagonist used in the
clinic, has been reported to increase glutamate release indepen-
dently from its effect on locomotor activity inmice (Schobel et al.,
2013). Both MK-801 and ketamine have been used as animal
models for psychosis at doses that produce substantial increase of
glutamate release (Large, 2007). Interestingly, ketamine has been
reported to have rapid antidepressant properties at low dosage
in patients resistant to antidepressive treatment (Salvadore and
Singh, 2013). The mechanism for this antidepressant action is
not fully elucidated, in particular in reference to its effect on
glutamate release.
In this study, we conducted the experiments during the light
cycle when orexin neurons are less active (Lee et al., 2005).
Interestingly, the OX1 receptor antagonist only partially blunted
the effect of MK-801 on glutamate release. During the dark phase
when orexin neurons are more active we postulate that the effect
of the OX1 receptor antagonist on blunting MK-801 induced
glutamate release might be more pronounced. However, other
neurochemicals and/or receptors might be involved in this com-
plex phenomenon as suggested by the data obtained in OX1
receptor knockout mice where MK-801 response was only par-
tially diminished compared to the response obtained in wild-type
animals. The partial response observed in knockout mice or after
antagonist administration supports the view that the action of
orexin is modulatory.
Evidences for glutamate and orexins co-localization and co-
release from orexin terminals in the locus coeruleus have been
presented (Henny et al., 2010). Orexins neurons originating from
the hypothalamus and projecting to the cortex contain both
orexins and glutamate. Interactions between orexinergic and glu-
tamatergic neurons have been described in the locus coeruleus,
amygdala and in the bed nucleus of the stria terminalis (John
et al., 2003; Tose et al., 2009; Lungwitz et al., 2012). In locus
coeruleus, the OX1 receptor is the only OX receptor present
(Marcus et al., 2001). In amygdala, bed nucleus of the stria ter-
minalis, and cortex both OX receptors are present (Trivedi et al.,
1998; Marcus et al., 2001). Future studies should examine the
potential contribution of the OX2 receptor in addition to the role
of the OX1 receptor.
Activity of orexin neurons is increased under stressful stimuli
leading to release of more orexins in terminal fields located in the
limbic system. It has been postulated that an abnormal persistence
of excessive release of orexins could lead to pathological anxiety or
panic attacks (Johnson et al., 2012). Emerging data indicate that
the anxiogenic properties of orexins are mediated through inter-
action with the glutamatergic system and that engagement of the
OX1 receptor is needed (Lungwitz et al., 2012). The present study
focused on the orexins/glutamate interaction in cortex, and this
important interaction is likely to be involved with arousal during
stress or attention to a stressor. Contribution of the OX2 recep-
tor for the orexin/glutamate interaction still needs to be studied
but from a therapeutic standpoint it is well established that block-
ing the OX2 receptor will lead to an hypnotic effect (Hoyer and
Jacobson, 2013; Dugovic et al., 2014) whereas in contrast selective
OX1 receptor blockade does not alter spontaneous sleep. Selective
targeting of the OX1 receptor with an antagonist may normalize
hyperglutamatergic states without hypnotic effect and thus may
represent a novel therapeutic strategy for the treatment of various
psychiatric disorders associated with hyperactive states.
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